Rodman & Renshaw analyst Seema Sheoran initiated coverage of Camp4 Therapeutics with a Buy rating and $7 price target, implying 55% upside. Camp4 is developing antisense oligonucleotides that target regulatory RNAs, the analyst tells investors in a research note.
